StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) stock

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$11.74−1.01 (-7.92%)

Close on Nov 17, 2026Market cap $79.70MP/E –Yield –

Earnings

Eloxx Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q1 FY2023
–
EPS, Q1 FY2023
-$2.88
$0.14 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Eloxx Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 11, 2026during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 13, 2023during market hours–––Release
Q1 FY2023ended Mar 31, 2023May 16, 2023during market hours––-$2.88Release
Q4 FY2022ended Dec 31, 2022Apr 3, 2023before the open––-$2.92Release
Q3 FY2022ended Sep 30, 2022Nov 14, 2022during market hours––-$0.09Release
Q2 FY2022ended Jun 30, 2022Aug 15, 2022during market hours––-$0.12Release
Q1 FY2022ended Mar 31, 2022Apr 4, 2022before the open––$0.14Release
Q3 FY2021ended Sep 30, 2021Nov 9, 2021before the open––-$0.11Release
Q2 FY2021ended Jun 30, 2021Aug 17, 2021after the close–––Filing
Q1 FY2021ended Mar 31, 2021May 7, 2021after the close–––Filing
Q4 FY2020ended Dec 31, 2020Mar 11, 2021during market hours–––Filing
Q3 FY2020ended Sep 30, 2020Nov 5, 2020during market hours–––Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Eloxx Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Eloxx Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Eloxx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?